TSW
ROIV icon

Thompson Siegel & Walmsley’s Roivant Sciences ROIV Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-282,624
Closed -$4.28M – 424
2025
Q3 		$4.28M Sell
282,624
-244,450
-46% -$3.03M 0.07% 239
2025
Q2 		$5.94M Sell
527,074
-5,690
-1% -$61.7K 0.1% 195
2025
Q1 		$5.38M Sell
532,764
-32,573
-6% -$352K 0.09% 181
2024
Q4 		$6.69M Buy
565,337
+51,705
+10% +$611K 0.1% 167
2024
Q3 		$5.93M Buy
+513,632
New +$5.85M 0.09% 183

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Thompson Siegel & Walmsley's ROIV Position: Q4 2025 in Review

Thompson Siegel & Walmsley sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 282,624 shares — an estimated $4.28M sold.

Thompson Siegel & Walmsley first reported a position in ROIV in Q3 2024 and held it in 5 quarters. The position peaked at $6.69M in Q4 2024. 399 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

  • Thompson Siegel & Walmsley reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 282,624 Roivant Sciences shares in Q4 2025, an estimated $4.28M.
  • Thompson Siegel & Walmsley first reported a position in Roivant Sciences in Q3 2024 and held it in 5 quarters.
  • Thompson Siegel & Walmsley's Roivant Sciences position peaked at $6.69M in Q4 2024.
  • 399 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2025, filed 10 Feb 2026.